GrayMatters Health develops Prism for PTSD™, the first FDA-cleared self-neuromodulation device that utilizes an amygdala-based digital biomarker to help patients regulate brain activity associated with post-traumatic stress disorder symptoms. This technology enhances standard mental health therapies, resulting in clinically significant symptom improvement for 67% of patients within three months of treatment.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals suffering from Post-Traumatic Stress Disorder (PTSD) struggle to regulate the brain activity associated with their symptoms, even with standard mental health therapies. Current treatment options may not provide sufficient or targeted relief for all patients.
Solution
GrayMatters Health offers Prism for PTSD™, an FDA-cleared, self-neuromodulation device designed to help patients learn to regulate brain activity linked to PTSD symptoms. The technology utilizes a digital biomarker based on amygdala activity to provide targeted feedback during therapy sessions. By augmenting standard mental healthcare, Prism aims to improve patient outcomes by enabling individuals to gain greater control over their neurological responses to traumatic memories and triggers. The device is intended for use under the guidance of a healthcare professional as an adjunct treatment.
Target Audience
The primary users are mental healthcare professionals, such as psychiatrists and therapists, who treat patients with PTSD, as well as the patients themselves who are seeking adjunctive treatment options.
Features
- Self-neuromodulation device utilizing a digital biomarker of amygdala activity
- Real-time feedback to help patients regulate brain activity associated with PTSD symptoms
- Non-invasive and does not re-expose patients to trauma
- Designed to augment standard mental health therapies
- Clinically significant symptom improvement observed in 67% of patients within three months in clinical trials
- Can be operated by a non-MD
- Mild and self-resolved side effects